Bleomycin

Last updated

Bleomycin
Bleomycin A2.svg
Bleomycin A2
Clinical data
Trade names Blenoxane
AHFS/Drugs.com Monograph
MedlinePlus a682125
License data
Pregnancy
category
Routes of
administration
intravenous, intramuscular, subcutaneous, intrapleural [2]
Drug class Glycopeptide antibiotic
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 100% and 70% following intramuscular and subcutaneous administrations, respectively, and 45% following both intraperitoneal and intrapleural administrations [2]
Elimination half-life two hours [2]
Excretion Kidney (60–70%) [2]
Identifiers
  • (3-{[(2'-{(5S,8S,9S,10R,13S)-15-{6-amino-2- [(1S)-3-amino-1-{[(2S)-2,3-diamino-3-oxopropyl]amino}-3-oxopropyl] -5-methylpyrimidin-4-yl}-13-[{[(2R,3S,4S,5S,6S)-3- {[(2R,3S,4S,5R,6R)-4-(carbamoyloxy)-3,5-dihydroxy-6- (hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy} -4,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl]oxy} (1H-imidazol-5-yl)methyl]-9-hydroxy-5-[(1R)-1-hydroxyethyl]-8,10-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazapentadec-1-yl}-2,4'-bi-1,3-thiazol-4-yl)carbonyl]amino}propyl)(dimethyl)sulfonium
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C55H84N17O21S3
Molar mass 1415.56 g·mol−1
3D model (JSmol)
  • CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H](C(C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O
  • InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41-,42-,43-,53+,54-/m0/s1 X mark.svgN
  • Key:OYVAGSVQBOHSSS-UAPAGMARSA-O X mark.svgN
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Bleomycin is a medication primarily used to treat cancer. [6] This includes Hodgkin's lymphoma, non-Hodgkin's lymphoma, testicular cancer, ovarian cancer, and cervical cancer among others. [6] Typically used with other cancer medications, [6] it can be given intravenously, by injection into a muscle or under the skin. [6] It may also be administered inside the chest to help prevent the recurrence of a pleural effusion due to cancer; however talc is better for this. [6] [7] It may sometimes be used to treat other difficult-to-treat skin lesions such as plantars warts in immunocompromised patients.

Contents

Common side effects include fever, weight loss, vomiting, and rash. [6] A severe type of anaphylaxis may occur. [6] It may also cause inflammation of the lungs that can result in lung scarring. [6] Chest X-rays every couple of weeks are recommended to check for this. [6] Bleomycin may cause harm to the baby if used during pregnancy. [6] It is believed to primarily work by preventing the synthesis of DNA. [6]

Bleomycin was discovered in 1962. [8] [9] It is on the World Health Organization's List of Essential Medicines. [10] It is available as a generic medication. [6] It is made by the bacterium Streptomyces verticillus . [6]

Medical uses

Cancer

Bleomycin is mostly used to treat cancer. [6] This includes testicular cancer, ovarian cancer, and Hodgkin's disease, and less commonly non-Hodgkin's disease. [6] It can be given intravenously, by intramuscular injection, or under the skin. [6]

Other uses

It may also be put inside the chest to help prevent the recurrence of a pleural effusion due to cancer. [6] However, for scarring down the pleura, talc appears to be the better option although indwelling pleural catheters are at least as effective in reducing the symptoms of an effusion(such as dyspnea). [11] [12]

While potentially effective against bacterial infections, its toxicity prevents its use for this purpose. [6] It has been studied in the treatment of warts but is of unclear benefit. [13]

Side effects

The most common side effects are flu-like symptoms and include fever, rash, dermatographism, hyperpigmentation, alopecia (hair loss), chills, and Raynaud's phenomenon (discoloration of fingers and toes). The most serious complication of bleomycin, occurring upon increasing dosage, is pulmonary fibrosis and impaired lung function. It has been suggested that bleomycin induces sensitivity to oxygen toxicity [14] and recent studies support the role of the proinflammatory cytokines IL-18 and IL-1beta in the mechanism of bleomycin-induced lung injury. [15] Any previous treatment with bleomycin should therefore always be disclosed to the anaesthetist prior to undergoing a procedure requiring general anaesthesia. Due to the oxygen sensitive nature of bleomycin, and the theorised increased likelihood of developing pulmonary fibrosis following supplemental oxygen therapy, it has been questioned whether patients should take part in scuba diving following treatment with the drug. [16] Bleomycin has also been found to disrupt the sense of taste. [17]

Lifetime cumulative dose

Bleomycin should not exceed a lifetime cumulative dose greater than 400 units. [18] Pulmonary toxicities, most commonly presenting as pulmonary fibrosis, are associated with doses of bleomycin greater than 400 units. [18]

Mechanism of action

Bleomycin acts by induction of DNA strand breaks. [19] Some studies suggest bleomycin also inhibits incorporation of thymidine into DNA strands. DNA cleavage by bleomycin depends on oxygen and metal ions, at least in vitro. The exact mechanism of DNA strand scission is unresolved, but it has been suggested that bleomycin chelates metal ions (primarily iron), producing a pseudoenzyme that reacts with oxygen to produce superoxide and hydroxide free radicals that cleave DNA. An alternative hypothesis states that bleomycin may bind at specific sites in the DNA strand and induce scission by abstracting the hydrogen atom from the base, resulting in strand cleavage as the base undergoes a Criegee-type rearrangement, or forms an alkali-labile lesion. [20]

Biosynthesis

Biosynthesis of bleomycin is completed by glycosylation of the aglycones. Bleomycin naturally occurring-analogues have two to three sugar molecules, and DNA cleavage activities of these analogues have been assessed, [21] [22] primarily by the plasmid relaxation and break light assays.

History

Bleomycin was first discovered in 1962 when the Japanese scientist Hamao Umezawa found anticancer activity while screening culture filtrates of Streptomyces verticillus . Umezawa published his discovery in 1966. [23] The drug was launched in Japan by Nippon Kayaku in 1969. In the US, bleomycin gained FDA approval in July 1973. It was initially marketed in the US by the Bristol-Myers Squibb precursor, Bristol Laboratories, under the brand name Blenoxane.

Research

Bleomycin is used in research to induce pulmonary fibrosis in mice. [24]

See also

Related Research Articles

<span class="mw-page-title-main">Chemotherapy</span> Treatment of cancer using drugs that inhibit cell division or kill cells

Chemotherapy is the type of cancer treatment that uses one or more anti-cancer drugs in a standard regimen. Chemotherapy may be given with a curative intent, or it may aim only to prolong life or to reduce symptoms. Chemotherapy is one of the major categories of the medical discipline specifically devoted to pharmacotherapy for cancer, which is called medical oncology.

<span class="mw-page-title-main">Pneumonia</span> Inflammation of the alveoli of the lungs

Pneumonia is an inflammatory condition of the lung primarily affecting the small air sacs known as alveoli. Symptoms typically include some combination of productive or dry cough, chest pain, fever, and difficulty breathing. The severity of the condition is variable.

<span class="mw-page-title-main">Pleurisy</span> Disease of the lungs

Pleurisy, also known as pleuritis, is inflammation of the membranes that surround the lungs and line the chest cavity (pleurae). This can result in a sharp chest pain while breathing. Occasionally the pain may be a constant dull ache. Other symptoms may include shortness of breath, cough, fever, or weight loss, depending on the underlying cause. Pleurisy can be caused by a variety of conditions, including viral or bacterial infections, autoimmune disorders, and pulmonary embolism.

<span class="mw-page-title-main">Pleural effusion</span> Accumulation of excess fluid in the pleural cavity

A pleural effusion is accumulation of excessive fluid in the pleural space, the potential space that surrounds each lung. Under normal conditions, pleural fluid is secreted by the parietal pleural capillaries at a rate of 0.6 millilitre per kilogram weight per hour, and is cleared by lymphatic absorption leaving behind only 5–15 millilitres of fluid, which helps to maintain a functional vacuum between the parietal and visceral pleurae. Excess fluid within the pleural space can impair inspiration by upsetting the functional vacuum and hydrostatically increasing the resistance against lung expansion, resulting in a fully or partially collapsed lung.

<span class="mw-page-title-main">Granisetron</span> Serotonin 5-HT3 antiemetic

Granisetron is a serotonin 5-HT3 receptor antagonist used as an antiemetic to treat nausea and vomiting following chemotherapy and radiotherapy. Its main effect is to reduce the activity of the vagus nerve, which is a nerve that activates the vomiting center in the medulla oblongata. It does not have much effect on vomiting due to motion sickness. This drug does not have any effect on dopamine receptors or muscarinic receptors.

Transient tachypnea of the newborn is a respiratory problem that can be seen in the newborn shortly after delivery. It is caused by retained fetal lung fluid due to impaired clearance mechanisms. It is the most common cause of respiratory distress in term neonates. It consists of a period of tachypnea. Usually, this condition resolves over 24–72 hours. Treatment is supportive and may include supplemental oxygen and antibiotics. The chest x-ray shows hyperinflation of the lungs including prominent pulmonary vascular markings, flattening of the diaphragm, and fluid in the horizontal fissure of the right lung.

<span class="mw-page-title-main">Interstitial lung disease</span> Diseases of the space or tissue between the alveoli of the lungs

Interstitial lung disease (ILD), or diffuse parenchymal lung disease (DPLD), is a group of respiratory diseases affecting the interstitium and space around the alveoli of the lungs. It concerns alveolar epithelium, pulmonary capillary endothelium, basement membrane, and perivascular and perilymphatic tissues. It may occur when an injury to the lungs triggers an abnormal healing response. Ordinarily, the body generates just the right amount of tissue to repair damage, but in interstitial lung disease, the repair process is disrupted, and the tissue around the air sacs (alveoli) becomes scarred and thickened. This makes it more difficult for oxygen to pass into the bloodstream. The disease presents itself with the following symptoms: shortness of breath, nonproductive coughing, fatigue, and weight loss, which tend to develop slowly, over several months. The average rate of survival for someone with this disease is between three and five years. The term ILD is used to distinguish these diseases from obstructive airways diseases.

<span class="mw-page-title-main">Vinblastine</span> Chemotherapy medication

Vinblastine (VBL), sold under the brand name Velban among others, is a chemotherapy medication, typically used with other medications, to treat a number of types of cancer. This includes Hodgkin's lymphoma, non-small-cell lung cancer, bladder cancer, brain cancer, melanoma, and testicular cancer. It is given by injection into a vein.

<span class="mw-page-title-main">Topotecan</span> Chemical compound

Topotecan, sold under the brand name Hycamtin among others, is a chemotherapeutic agent medication that is a topoisomerase inhibitor. It is a synthetic, water-soluble analog of the natural chemical compound camptothecin. It is used in the form of its hydrochloride salt to treat ovarian cancer, lung cancer and other cancer types.

<span class="mw-page-title-main">Lomustine</span> Chemical compound

Lomustine is an alkylating nitrosourea compound used in chemotherapy. It is closely related to semustine and is in the same family as streptozotocin. It is a highly lipid-soluble drug, thus it crosses the blood–brain barrier. This property makes it ideal for treating brain tumors, which is its primary use, although it is also used to treat Hodgkin lymphoma as a second-line option. It has also been used in veterinary practice as a treatment for cancers in cats and dogs.

ABVD is a chemotherapy regimen used in the first-line treatment of Hodgkin lymphoma, replacing the older MOPP protocol. It consists of concurrent treatment with the chemotherapy drugs:

<span class="mw-page-title-main">Non-small-cell lung cancer</span> Any type of epithelial lung cancer other than small-cell lung carcinoma

Non-small-cell lung cancer (NSCLC), or non-small-cell lung carcinoma, is any type of epithelial lung cancer other than small-cell lung cancer (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small-cell carcinoma. When possible, they are primarily treated by surgical resection with curative intent, although chemotherapy has been used increasingly both preoperatively and postoperatively.

<span class="mw-page-title-main">Dasatinib</span> Chemical compound

Dasatinib, sold under the brand name Sprycel among others, is a targeted therapy medication used to treat certain cases of chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL). Specifically it is used to treat cases that are Philadelphia chromosome-positive (Ph+). It is taken by mouth.

Malignant pleural effusion is a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue (pleura) lining the outside of the lung and the wall of the chest cavity. Lung cancer and breast cancer account for about 50-65% of malignant pleural effusions. Other common causes include pleural mesothelioma and lymphoma.

<span class="mw-page-title-main">Polypeptide antibiotic</span> Class of antibiotics

Polypeptide antibiotics are a chemically diverse class of anti-infective and antitumor antibiotics containing non-protein polypeptide chains. Examples of this class include actinomycin, bacitracin, colistin, and polymyxin B. Actinomycin-D has found use in cancer chemotherapy. Most other polypeptide antibiotics are too toxic for systemic administration, but can safely be administered topically to the skin as an antiseptic for shallow cuts and abrasions.

Brentuximab vedotin, sold under the brand name Adcetris, is an antibody-drug conjugate medication used to treat relapsed or refractory Hodgkin lymphoma (HL) and systemic anaplastic large cell lymphoma (ALCL), a type of T cell non-Hodgkin lymphoma. It selectively targets tumor cells expressing the CD30 antigen, a defining marker of Hodgkin lymphoma and ALCL. The drug is being jointly marketed by Millennium Pharmaceuticals outside the US and by Seagen in the US.

<span class="mw-page-title-main">Pirfenidone</span> Chemical compound

Pirfenidone, sold under the brand name Pirespa among others, is a medication used for the treatment of idiopathic pulmonary fibrosis. It works by reducing lung fibrosis through downregulation of the production of growth factors and procollagens I and II.

<span class="mw-page-title-main">Pingyangmycin</span> Glycopeptide antibiotic used to treat various cancers

Pingyangmycin (also known as bleomycin A5) is an antitumor glycopeptide antibiotic belonging to the bleomycin family, which is produced by Streptomyces verticillus var. pingyangensis n.sp., a variety of Streptomyces verticillus. It was discovered in 1969 at Pingyang County of Zhejiang Province in China, and was brought into clinical use in 1978.

<span class="mw-page-title-main">Asbestos-related diseases</span> Medical condition

Asbestos-related diseases are disorders of the lung and pleura caused by the inhalation of asbestos fibres. Asbestos-related diseases include non-malignant disorders such as asbestosis, diffuse pleural thickening, pleural plaques, pleural effusion, rounded atelectasis and malignancies such as lung cancer and malignant mesothelioma.

Streptomyces verticillus is a species of Gram-positive bacteria in the genus Streptomyces. Whilst screening fermentation broths of this species for bioactivity in the early 1960s, Hamao Umezawa and colleagues at the Institute of Microbial Chemistry in Tokyo identified a family of glycopeptide antitumor antibiotics called the bleomycins. Examples of the bleomycins in clinical use include bleomycin A2 (also known as bleomycin) and bleomycin A5 (also known as pingyangmycin). Both are used to treat lymphomas (e.g. Hodgkin's lymphoma), head and neck cancer, and testicular cancer.

References

  1. "Bleomycin Use During Pregnancy". Drugs.com. 9 August 2019. Retrieved 16 February 2020.
  2. 1 2 3 4 "Bleomycin- bleomycin sulfate injection, powder, lyophilized, for solution". DailyMed. 31 December 2019. Retrieved 16 February 2020.
  3. "Bleo-Kyowa Powder for solution for injection - Summary of Product Characteristics (SmPC)". (emc). 31 August 2018. Archived from the original on 16 February 2020. Retrieved 16 February 2020.
  4. "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  5. "Bleomycin". European Medicines Agency (EMA).
  6. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 "Bleomycin Sulfate". The American Society of Health-System Pharmacists. Archived from the original on 8 September 2015. Retrieved 1 August 2015.
  7. Dipper A, Jones HE, Bhatnagar R, Preston NJ, Maskell N, Clive AO (April 2020). "Interventions for the management of malignant pleural effusions: a network meta-analysis". The Cochrane Database of Systematic Reviews. 2020 (4): CD010529. doi:10.1002/14651858.CD010529.pub3. PMC   7173736 . PMID   32315458.
  8. Sneader W (2005). Drug discovery : a history (Rev. and updated ed.). Chichester: Wiley. p. 312. ISBN   9780471899792. Archived from the original on 5 March 2016.
  9. Phillips GO (2018). Innovation and Technology Transfer in Japan and Europe: Industry-Academic Interactions. Routledge. p. PT155. ISBN   9780429774546.
  10. World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl: 10665/325771 . WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
  11. Shaw P, Agarwal R (2004). Shaw PH (ed.). "Pleurodesis for malignant pleural effusions". The Cochrane Database of Systematic Reviews (1): CD002916. doi:10.1002/14651858.CD002916.pub2. PMID   14973997. (Retracted, see doi:10.1002/14651858.CD002916.pub3, PMID   24259053)
  12. Thomas R, Murray K, Lee YC (April 2018). "Treatment Approaches for Malignant Pleural Effusion". JAMA. 319 (14): 1507–1508. doi:10.1001/jama.2018.1323. PMID   29634827.
  13. Kwok CS, Gibbs S, Bennett C, Holland R, Abbott R (September 2012). "Topical treatments for cutaneous warts". The Cochrane Database of Systematic Reviews. 9 (9): CD001781. doi:10.1002/14651858.CD001781.pub3. PMC   8101088 . PMID   22972052.
  14. Thompson M. "Bleomycin and Anaesthesia" (PDF). Anaesthesia Western Australia. Archived from the original (PDF) on 8 September 2017. Retrieved 8 September 2017.
  15. Hoshino T, Okamoto M, Sakazaki Y, Kato S, Young HA, Aizawa H (December 2009). "Role of proinflammatory cytokines IL-18 and IL-1beta in bleomycin-induced lung injury in humans and mice". American Journal of Respiratory Cell and Molecular Biology. 41 (6): 661–670. doi:10.1165/rcmb.2008-0182OC. PMC   10283344 . PMID   19265174.
  16. Huls G, ten Bokkel Huinink D (February 2003). "Bleomycin and scuba diving: to dive or not to dive?". The Netherlands Journal of Medicine. 61 (2): 50–53. PMID   12735422.
  17. Ackerman BH, Kasbekar N (1997). "Disturbances of taste and smell induced by drugs". Pharmacotherapy. 17 (3): 482–496. doi:10.1002/j.1875-9114.1997.tb03058.x. PMID   9165552. S2CID   12671326.
  18. 1 2 "bleomycin [TUSOM | Pharmwiki]". tmedweb.tulane.edu. Retrieved 2 February 2022.
  19. Takimoto CH, Calvo E (2008). "Principles of Oncologic Pharmacotherapy". In Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (eds.). Cancer Management: A Multidisciplinary Approach. Vol. 3 (11th ed.). UBM Medica LLC. Archived from the original on 15 May 2009.
  20. Hecht SM (January 2000). "Bleomycin: new perspectives on the mechanism of action". Journal of Natural Products. 63 (1): 158–168. doi:10.1021/np990549f. PMID   10650103.
  21. Hindra, Yang D, Teng Q, Dong LB, Crnovčić I, Huang T, et al. (March 2017). "Genome Mining of Streptomyces mobaraensis DSM40847 as a Bleomycin Producer Providing a Biotechnology Platform To Engineer Designer Bleomycin Analogues". Organic Letters. 19 (6): 1386–1389. doi:10.1021/acs.orglett.7b00283. PMID   28256838.
  22. Yang D, Hindra, Dong LB, Crnovcic I, Shen B (August 2017). "Engineered production and evaluation of 6'-deoxy-tallysomycin H-1 revealing new insights into the structure-activity relationship of the anticancer drug bleomycin". The Journal of Antibiotics. 71: 97–103. doi:10.1038/ja.2017.93. PMID   28831149. S2CID   33531845.
  23. Umezawa H, Maeda K, Takeuchi T, Okami Y (September 1966). "New antibiotics, bleomycin A and B". The Journal of Antibiotics. 19 (5): 200–9. PMID   5953301.
  24. Song N, Liu J, Shaheen S, Du L, Proctor M, Roman J, et al. (August 2015). "Vagotomy attenuates bleomycin-induced pulmonary fibrosis in mice". Scientific Reports. 5: 13419. Bibcode:2015NatSR...513419S. doi:10.1038/srep13419. PMC   4542162 . PMID   26289670. In our studies, mice developed classic PF with structural alteration of the lung following intravenous bleomycin treatment

Further reading